FDA GLP-1 Approval Timeline: Every Approval Since 2014
Complete FDA GLP-1 approval timeline from 2014 to 2026 — every semaglutide, tirzepatide, and liraglutide approval with dates, indications, and what each means for patients.
Written by Trimi Medical Team. Medically reviewed by Dr. Asad Niazi, MD, MPH. Timeline updated as new approvals occur.
Quick links: Semaglutide treatment, tirzepatide treatment, and FDA compounding rules 2026.
More on GLP-1 Regulatory Landscape
The FDA GLP-1 Revolution: A Regulatory Timeline
The FDA's approval of GLP-1 receptor agonists for weight management represents one of the most significant regulatory developments in obesity medicine history. Understanding this timeline helps patients appreciate the depth of clinical evidence behind these medications and the rigorous review process they have undergone before reaching the market.
GLP-1 receptor agonists were originally developed for type 2 diabetes management, where their blood sugar-lowering effects were the primary therapeutic target. When researchers noticed significant weight loss as a beneficial side effect, the pharmaceutical industry began specifically studying these medications for obesity — leading to the landmark trials and approvals that have transformed weight management.
This timeline covers every major FDA approval for GLP-1 and related medications, from the earliest approvals through the most recent developments, giving patients a comprehensive understanding of the regulatory landscape that governs the medications available through providers like Trimi.
Complete FDA GLP-1 Approval Timeline
December 2014
Saxenda (liraglutide 3.0 mg) approved for chronic weight management — the first GLP-1 medication specifically approved for obesity
December 2017
Ozempic (semaglutide 0.5/1.0 mg) approved for type 2 diabetes — sets the stage for weight loss research at higher doses
June 2021
Wegovy (semaglutide 2.4 mg) approved for chronic weight management — a landmark approval based on the STEP trial program showing 15% average weight loss
May 2022
Mounjaro (tirzepatide) approved for type 2 diabetes — the first dual GIP/GLP-1 receptor agonist
March 2023
Wegovy receives expanded approval for cardiovascular risk reduction in overweight/obese adults based on SELECT trial data
November 2023
Zepbound (tirzepatide) approved for chronic weight management — based on SURMOUNT trials showing up to 22.5% weight loss
December 2023
Wegovy approved for adolescents 12 years and older with obesity
2024-2025
Multiple supplemental approvals expand indications; oral semaglutide studies advance; next-generation compounds enter late-stage trials
What Each Approval Means for Patients
Each FDA approval represents years of clinical research, thousands of study participants, and rigorous safety review. For patients considering GLP-1 treatment, this approval history demonstrates that these medications have been extensively studied and proven both safe and effective for weight management when used as directed.
The progression from diabetes-only approvals to dedicated weight management approvals reflects the growing recognition that obesity is a chronic medical condition deserving of pharmacological treatment. This shift in regulatory and medical perspective has been essential in destigmatizing obesity treatment and expanding access through platforms like Trimi.
For patients, the practical takeaway is that semaglutide and tirzepatide are among the most thoroughly studied medications in their class, with robust safety data from trials involving tens of thousands of participants. This evidence base is far stronger than what exists for most weight loss interventions that have been marketed over the decades.
The Compounding Dimension
While the FDA approval timeline governs brand-name medications, the parallel development of compounding pharmacy regulations has created an additional access pathway for patients. When the FDA recognized shortages of semaglutide and tirzepatide — driven by unprecedented demand — compounding pharmacies were authorized to produce these medications under specific regulatory conditions.
This compounding authorization has been critical in making GLP-1 treatment accessible to millions of patients who cannot afford brand-name pricing of $1,000 or more per month. The regulatory status of compounded GLP-1 medications is subject to change as supply conditions evolve, which is why staying informed through your provider is important. For current compounding regulations, see our guide on FDA compounding rules in 2026.
What is Coming Next
The GLP-1 pipeline is the most active in pharmaceutical history for obesity treatment. Several next-generation compounds are in advanced clinical trials, including oral formulations of existing medications, triple-agonist compounds targeting GLP-1, GIP, and glucagon receptors simultaneously, and novel peptides with potentially even greater efficacy. For a look at what is on the horizon, see our article on the future of weight loss.
Bottom Line
The FDA GLP-1 approval timeline tells a story of scientific progress and expanding patient access. From the first obesity-specific approval in 2014 to the most recent developments, each milestone has strengthened the evidence base and broadened treatment options. Patients today have access to thoroughly studied, FDA-reviewed medications through both brand-name and compounded pathways. Trimi makes these evidence-based treatments accessible at $149 per month through specialized metabolic health providers.
Frequently Asked Questions
When was semaglutide first approved by the FDA?
Semaglutide was first approved for type 2 diabetes as Ozempic in December 2017. It was later approved specifically for chronic weight management as Wegovy in June 2021 at a higher dose (2.4 mg weekly). These are the same molecule at different doses for different indications.
When was tirzepatide approved for weight loss?
Tirzepatide was approved for weight loss as Zepbound in November 2023. It had previously been approved for type 2 diabetes as Mounjaro in May 2022. The weight loss approval followed the publication of the SURMOUNT trial results showing superior efficacy.
What GLP-1 medications are currently FDA-approved for weight loss?
As of early 2026, FDA-approved GLP-1 medications for chronic weight management include Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide), and Saxenda (liraglutide 3.0 mg). Compounded versions of semaglutide and tirzepatide are available under FDA compounding regulations during drug shortages.
How does FDA approval affect compounded GLP-1?
FDA-approved brand-name GLP-1 medications and compounded versions coexist in the market. Compounded semaglutide is legally available when there is an FDA-recognized shortage of the branded product. The regulatory status of compounded versions could change if shortages are resolved, which is why patients should stay informed through their provider.
Are more GLP-1 medications expected to be approved?
Several next-generation GLP-1 and multi-receptor agonist medications are in clinical trials, including oral versions of semaglutide for weight loss and triple-agonist compounds. The obesity medication pipeline is more active than at any point in history, with several compounds expected to seek FDA approval in the coming years.
Why does the FDA approval process matter for patients?
FDA approval establishes the safety and efficacy of a medication through rigorous clinical trial review. It determines which medications can be legally marketed, what indications they can be prescribed for, and what safety monitoring is required. Understanding the approval status helps patients make informed treatment decisions.
How can I access FDA-approved GLP-1 medications affordably?
Brand-name FDA-approved GLP-1 medications are expensive ($1,000+ per month without insurance). Compounded versions available through telehealth providers like Trimi offer the same active ingredients at a fraction of the cost — starting at $149 per month. This makes evidence-based GLP-1 treatment accessible regardless of insurance coverage.
Sources & References
Medical Disclaimer: This content is for educational purposes only and does not constitute medical or legal advice. FDA regulations change — verify current regulatory status with official FDA sources. Trimi offers GLP-1 treatment — readers should be aware of our perspective.